Ustalenie właściwego, czyli skutecznego i bezpiecznego leczenia przeciwkrzepliwego stanowi często złożony, interdyscyplinarny problem. Terapia doustnymi antykoagulantami niebędącymi antagonistami witaminy K, preparatami bezpieczniejszymi i co najmniej tak skutecznymi jak warfaryna stwarza pewne możliwości, nie jest jednak pozbawiona ograniczeń i powikłań. W niniejszej pracy zaprezentowano przypadki pacjentek w wieku 45 i 86 lat, których leczenie wymagało szerokich działań ze strony zarówno neurologów, jak i kardiologów, a dobór odpowiedniej terapii antykoagulacyjnej był trudny.Determining proper, i.e. effective and safe anticoagulant therapy is often complex interdisciplinary problem. New oral anticoagulants are safer and at least as effect...
Introduction of new oral anticoagulants (Non-Vitamin K Antagonist Oral Anticoagulants- NOACs) helped...
A family physician who systematically takes care of elderly patients with progressive dementia, stro...
Non-vitamin K antagonist oral anticoagulants (NOAC) are no longer a new topic in clinical practice. ...
Due to the common use of oral anticoagulants in the treatment of vascular diseases and their complic...
Nowe doustne leki przeciwzakrzepowe od kilku lat zastępują tradycyjne antykoagulanty, będące antagon...
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent ...
Nowadays, anticoagulant therapy is one of the most common form of medical intervention. Among others...
The first step of anticoagulant therapy is to make a therapeutic decision based on absolute risk of ...
Non-vitamin K oral antagonist anticoagulants (NOAC) demonstrated efficiency and safety in several cl...
Stroke is the nosological unit burdened high percentage of early mortality, difficult prognosis for ...
Nadciśnienie tętnicze jest istotnym czynnikiem ryzyka sercowo-naczyniowego. Skuteczność leczenia hip...
We present the case of 31-year-old man, with the intermediate-risk pulmonary embolism, as a consecut...
Obecnie najskuteczniejszą metodą leczenia udaru niedokrwiennego mózgu jest tromboliza z dożylnym pod...
Availability of interventional treatment, effective antiplatelet and anticoagulant agents resulted i...
Pulmonary embolism (PE) is an acute condition that requires rapid diagnosis and immediate treatment....
Introduction of new oral anticoagulants (Non-Vitamin K Antagonist Oral Anticoagulants- NOACs) helped...
A family physician who systematically takes care of elderly patients with progressive dementia, stro...
Non-vitamin K antagonist oral anticoagulants (NOAC) are no longer a new topic in clinical practice. ...
Due to the common use of oral anticoagulants in the treatment of vascular diseases and their complic...
Nowe doustne leki przeciwzakrzepowe od kilku lat zastępują tradycyjne antykoagulanty, będące antagon...
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent ...
Nowadays, anticoagulant therapy is one of the most common form of medical intervention. Among others...
The first step of anticoagulant therapy is to make a therapeutic decision based on absolute risk of ...
Non-vitamin K oral antagonist anticoagulants (NOAC) demonstrated efficiency and safety in several cl...
Stroke is the nosological unit burdened high percentage of early mortality, difficult prognosis for ...
Nadciśnienie tętnicze jest istotnym czynnikiem ryzyka sercowo-naczyniowego. Skuteczność leczenia hip...
We present the case of 31-year-old man, with the intermediate-risk pulmonary embolism, as a consecut...
Obecnie najskuteczniejszą metodą leczenia udaru niedokrwiennego mózgu jest tromboliza z dożylnym pod...
Availability of interventional treatment, effective antiplatelet and anticoagulant agents resulted i...
Pulmonary embolism (PE) is an acute condition that requires rapid diagnosis and immediate treatment....
Introduction of new oral anticoagulants (Non-Vitamin K Antagonist Oral Anticoagulants- NOACs) helped...
A family physician who systematically takes care of elderly patients with progressive dementia, stro...
Non-vitamin K antagonist oral anticoagulants (NOAC) are no longer a new topic in clinical practice. ...